Equities

Cartesian Therapeutics Inc

Cartesian Therapeutics Inc

Actions
  • Price (EUR)14.90
  • Today's Change-1.60 / -9.70%
  • Shares traded41.00
  • 1 Year change-40.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 15:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments77135128
Total Receivables, Net8.859.769.91
Total Inventory------
Prepaid expenses4.973.786.47
Other current assets, total------
Total current assets91148144
Property, plant & equipment, net121412
Goodwill, net48----
Intangibles, net151----
Long term investments2.002.002.00
Note receivable - long term------
Other long term assets00.030.09
Total assets305166160
LIABILITIES
Accounts payable3.150.320.22
Accrued expenses181612
Notes payable/short-term debt000
Current portion long-term debt/capital leases08.485.96
Other current liabilities, total470.5954
Total current liabilities682572
Total long term debt01820
Total debt02626
Deferred income tax16----
Minority interest------
Other liabilities, total3612945
Total liabilities44572137
SHAREHOLDERS EQUITY
Common stock0.020.020.01
Additional paid-in capital179493457
Retained earnings (accumulated deficit)(615)(395)(430)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(4.6)(4.56)(4.57)
Total equity(140)9423
Total liabilities & shareholders' equity305166160
Total common shares outstanding5.405.104.12
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.